China News Service, December 5th (Reporter Chen Jing) Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine takes the lead and joins 68 hospitals in Shanghai, Jiangsu, Zhejiang and Anhui to form the "Yangtze River Delta Urban Economic Coordination Association Smart Medical Development Alliance Urology Specialty Alliance "Unveiled on the 5th.
These alliance member hospitals will work together to achieve "standard integration of diagnosis and treatment, homogeneity of discipline construction, collaboration of talent training, and intelligent diagnosis and treatment technology".
Kidney cancer is one of the common malignant tumors of the urinary system and one of the tumors with the highest mortality.
Kidney cancer patients have no obvious symptoms in the early stage, and they are generally found in the late stage. They are also called "silent killers."
The alliance members will take the standardized diagnosis and treatment of key diseases as the starting point, and continue to sink the supply of high-quality resources in clinical promotion, application of precision medicine, smart medicine and telemedicine, so that the people can get better in the integration and high-quality development of the Yangtze River Delta Medical services.
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine takes the lead and unites 68 hospitals in Shanghai, Jiangsu, Zhejiang and Anhui to achieve "integration of diagnosis and treatment standards, homogenization of discipline construction, collaboration of talent training, and intelligent diagnosis and treatment technology".
Photo courtesy of Renji Hospital
It is reported that in the past year, the Smart Medical Development Alliance of the Yangtze River Delta City Economic Coordination Association has established 6 specialties including gallstone disease, stroke, nuclear medicine and molecular imaging.
On the same day, the "2020 Renji Urology Forum" was held online and offline. About 500 experts from home and abroad participated online and offline to deliver speeches, exchanges and surgical demonstrations on the progress of diagnosis and treatment of urinary system malignant tumors.
Experts discussed the key and difficult issues of minimally invasive kidney-preserving treatment of kidney cancer and hereditary kidney cancer.
Zhang Jin, chief physician of the Department of Urology of Renji Hospital, said in an interview that day, in clinical practice, 5% to 8% of kidney cancer patients are hereditary kidney cancer.
Compared with other kidney cancers, patients with hereditary kidney cancer have an earlier onset and are multiple tumors on both sides, which is very difficult to treat.
The expert said that 90% of hereditary kidney cancer patients he saw in the clinic were found in physical examinations.
In clinical practice, 5% to 8% of kidney cancer patients are hereditary kidney cancer.
Photo courtesy of Renji Hospital
Zhang Jin said that hereditary kidney cancer is a dominant inheritance, which can be screened out through genetic testing at the embryonic stage and block its family inheritance.
Professor Xue Wei, director of the Department of Urology, Renji Hospital, told reporters that the hospital has established a database of hereditary kidney cancer diseases, which has included more than two hundred families.
Professor Xue Wei said that high-energy diets and lifestyle changes have made the incidence of kidney cancer tend to be younger. In the clinic, the youngest patients are only in their teens. Early kidney cancer is asymptomatic. The expert suggested that high-risk groups with family history should undergo routine ultrasound examinations as soon as possible. (Finish)